The Hellenic Competition Authority fines a pharmaceutical company for abuse of dominance in the market of migraine medicines (Glaxosmithline)

Decision concerning GLAXOSMITHKLINE SA and GLAXOSMITHKLINE plc’s supply policy of medicinal products LAMICTAL, IMIGRAN and SEREVENT in the Greek market, following the partial referral of the case back to the Hellenic Competition Commission (HCC) by the Athens Administrative Court of Appeals and the Council of State* Following decisions of the Athens Administrative Court of Appeals and of the Council of State, referring back to the HCC certain aspects of the Glaxo Greece case for a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Hellenic Competition Authority, The Hellenic Competition Authority fines a pharmaceutical company for abuse of dominance in the market of migraine medicines (Glaxosmithline), 11 July 2018, e-Competitions Bulletin July 2018, Art. N° 87385

Visites 323

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues